Table 2.
Comparison of immune responses induced in NHPs.
| Vaccine candidate | ZEBOV antigen(s) | Vaccine doses (n) | Time to challenge (days) | Survival rate (%) | T cell response | Humoral response | Ref. |
|---|---|---|---|---|---|---|---|
| Inactivated virus | Whole virus | 3 | 78 | 25 | n.a. | + | [8] |
| Virus-like particles | GP, NP, VP40 | 3 | 126 | 100 | + | +++ | [13] |
| Alphavirus replicon | GP | 1 | 28 | 100 | n.a. | ++ | [21] |
| DNA + rec. Adenovirus | GP | 4 | 224 | 100 | ++ | ++ | [29] |
| rec. Adenovirus | GP | 1 | 28 | 100 | +++ | ++ | [46] |
| rec. Vaccina virus | GP | 3 | 98 | 0 | n.a. | + | [8] |
| rec. Paramyxovirus | GP | 2 | 67 | 100 | + | ++ | [56] |
| rec. Vesicular stomatitis virus | GP | 1 | 28 | 100 | +/− | +++ | [72] |
| rec. Rabiesvirus | GP | 1 | 75 | 100 | +/− | +++ | [77] |
+: Contributing to protection; ++: Important for protection; +++: Critical for protection; +/−: Not conclusive; n.a.: Not analyzed.